Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3478 | 0.80 | TK1 (0.49) | TK1DHFR | |
| SCHEMBL2885 | 0.80 | TK1 (0.50) | TK1DHFR | |
| SCHEMBL31653059 | 0.78 | TK1 (0.56) | TK1 | |
| SCHEMBL4420067 | 0.78 | TK1 (0.56) | TK1 | |
| SCHEMBL4420063 | 0.78 | TK1 (0.56) | TK1 | |
| SCHEMBL3437022 | 0.78 | TK1 (0.56) | TK1 | |
| SCHEMBL3437019 | 0.78 | TK1 (0.56) | TK1 | |
| SCHEMBL2056793 | 0.77 | TK1 (0.52) | TK1 | |
| SCHEMBL2056794 | 0.77 | TK1 (0.52) | TK1 | |
| SCHEMBL26270604 | 0.77 | TK1 (0.52) | TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100080830-A1 | SYSTEMIC DELIVERY OF ANTIVIRAL AGENTS | PSIVIDA INC. (US) | 2010-04-01 | — | — | US | claimed |
| EP-1239840-B1 | ANTIVIRAL MEDICATION | ALZA CORP (US) | 2005-04-06 | — | — | EP | claimed |
| US-20040115268-A1 | Systemic delivery of antiviral agents | CONTROL DELIVERY SYSTEMS, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004043435-A2 | SYSTEMIC DELIVERY OF ANTIVIRAL AGENTS | CONTROL DELIVERY SYSTEMS, INC. (US) | 2004-05-27 | — | — | WO | claimed |
| US-20020071863-A1 | Antiviral medication | DONG LIANG C (US) | 2002-06-13 | — | — | US | claimed |
| US-5358721-A | Antiviral therapy | ALZA CORPORATION (US) | 1994-10-25 | — | — | US | claimed |
| US-20250313905-A1 | METHODS AND COMPOSITIONS FOR IMPROVED PSYCHOLOGICAL AND RESILIENCE MEASURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-10-09 | — | — | US | disclosed |
| US-12364717-B2 | Compositions and methods for inhibiting seizures | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-22 | — | — | US | disclosed |
| US-12292445-B2 | Methods of selecting subjects for treatment with metabolomic modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-06 | — | — | US | disclosed |
| EP-4525896-A1 | METHODS AND COMPOSITIONS FOR IMPROVED PSYCHOLOGICAL AND RESILIENCE MEASURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2025038777-A2 | PROBIOTICS AND METHODS TO REDUCE APPETITE | BLOOM SCIENCE, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-4509174-A2 | COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTH | The Regents of the University of California (US) | 2025-02-19 | — | — | EP | disclosed |
| US-12195814-B2 | Cell-free nucleic acids for the analysis of the human microbiome and components thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2005051234-A2 | INJECTABLE SUSTAINED RELEASE IMPLANT HAVING A BIOERODIBLE MATRIX CORE AND A BIOERODIBLE SKIN | CONTROL DELIVERY SYSTEMS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-1239840-B1 | ANTIVIRAL MEDICATION | ALZA CORP (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20040176341-A1 | Core surrounded by polymer exterior layers, coatings, or skins which are bioerodable or biodegradable; time-release drug delivery device | EYEPOINT PHARMACEUTICALS US, INC. | 2004-09-09 | — | — | US | disclosed |
| US-20040115268-A1 | Systemic delivery of antiviral agents | CONTROL DELIVERY SYSTEMS, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004043435-A2 | SYSTEMIC DELIVERY OF ANTIVIRAL AGENTS | CONTROL DELIVERY SYSTEMS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20020071863-A1 | Antiviral medication | DONG LIANG C (US) | 2002-06-13 | — | — | US | disclosed |
| US-5358721-A | Antiviral therapy | ALZA CORPORATION (US) | 1994-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080830-A1 | SYSTEMIC DELIVERY OF ANTIVIRAL AGENTS | HAVCR2, MAVS, PGF | TK1 18/4885DHFR 46/4885 |
| US-20040176341-A1 | Core surrounded by polymer exterior layers, coatings, or skins which are bioerodable or biodegradable; time-release drug delivery device | CUTA, PUF60, PGF | TK1 2648/4885DHFR 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.